Amgen awaits a make-or-break US verdict on its best-selling drug, while Cymabay looks for evidence that it could become a Nash contender.
Celgene stock falls 9%, suggesting that an activist campaign to derail its takeover by Bristol-Myers Squibb is reaching critical mass.
The immensely complex and long-running intertwined litigation between the two medtechs has been brought to an end.
Vantage’s roundup of medtech news you might have missed includes Boston Scientific hitting its 11th biz dev deal of the year.
The FDA has made a lot of noise about its plans to make medical devices safer. But these plans are somewhat amorphous; any meaningful steps would likely require…
US President Donald Trump’s blueprint offers various proposals to reduce drug prices, some more ambitious than others.
Unitary patents are important for the biopharma sector, but might be even more crucial for medtech.